Innovent Biologics Inc
- Indústria
- Pharmaceuticals
- Bolsa
- Hong Kong
- País / Região
- Hong Kong
- Funcionários
- 7.502
Faixa de valuation composta · conservador HK$60–HK$66 / justo HK$82–HK$112 / otimista HK$136–HK$150. A HK$97.05, Dentro da faixa de valor intrínseco justo.
Na publicação HK$89.35 (28 de julho de 2026)
Dados da EODHD, apresentados na moeda de reporte; apenas para referência, não constitui recomendação de investimento.
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
História
Em breveEsta seção está sendo preenchida — volte em breve.
Posição no setor
Em breveEsta seção está sendo preenchida — volte em breve.
Ainda não há análises sobre este ativo no seu idioma.